Literature DB >> 35151824

Sonodynamic therapy: Rapid progress and new opportunities for non-invasive tumor cell killing with sound.

Katherine M Nowak1, Mark R Schwartz2, Victoria R Breza2, Richard J Price3.   

Abstract

Solid tumor treatment relies heavily upon chemotherapies, radiation, surgical resection, and/or immunotherapies. Although many alternative non-invasive solid tumor therapies have been proposed through the years and continue to be tested in various contexts, tumor cell eradication remains a daunting task for the current cancer armamentarium. Indeed, solid tumors exhibit physically and biochemically heterogenous microenvironments, allowing them to easily acquire resistance mechanisms. Progress in sonodynamic therapy (SDT), a treatment modality capable of controlling tumor growth while limiting off-target effects and toxicities, has accelerated in recent years. SDT combines "sonosensitizing" agents with the non-invasive application of focused acoustic energy [i.e. focused ultrasound (FUS)] to drive highly localized formation of tumor cell-killing reactive oxygen species (ROS). Sonosensitizers selectively accumulate in tumor cells, after which FUS radiation eliminates the tumor by forcing the tumor cells to undergo cell death. In this article, we comprehensively review recent studies wherein SDT has been applied to treat primary and metastatic tumors. We discuss sonosensitizers, combination therapies with SDT, developments in defining the mechanism of SDT-induced cell cytotoxicity, and the promise SDT offers as a modulator of anti-tumor immunity.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Focused ultrasound; Immunogenic cell death; Immunotherapy; Photodynamic therapy; Sonosensitizers

Mesh:

Substances:

Year:  2022        PMID: 35151824      PMCID: PMC8918024          DOI: 10.1016/j.canlet.2022.215592

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   9.756


  70 in total

1.  Sonodynamic therapy inhibits angiogenesis and tumor growth in a xenograft mouse model.

Authors:  Zhongxiuzi Gao; Jinhua Zheng; Bin Yang; Zhu Wang; Haixia Fan; Yanhong Lv; Haixia Li; Limin Jia; Wenwu Cao
Journal:  Cancer Lett       Date:  2013-02-09       Impact factor: 8.679

2.  Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes.

Authors:  S Adachi; H Ito; M Tamamori-Adachi; Y Ono; T Nozato; S Abe; F Marumo; M Hiroe
Journal:  Circ Res       Date:  2001-03-02       Impact factor: 17.367

3.  Mitochondria-targeted high-load sound-sensitive micelles for sonodynamic therapy to treat triple-negative breast cancer and inhibit metastasis.

Authors:  Xiao Han; Zeyu Song; Ying Zhou; Yujing Zhang; Yulin Deng; Jieling Qin; Tao Zhang; Zhenqi Jiang
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2021-03-25       Impact factor: 7.328

4.  Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy.

Authors:  Keman Cheng; Yanping Ding; Ying Zhao; Shefang Ye; Xiao Zhao; Yinlong Zhang; Tianjiao Ji; Huanhuan Wu; Bin Wang; Gregory J Anderson; Lei Ren; Guangjun Nie
Journal:  Nano Lett       Date:  2018-04-26       Impact factor: 11.189

5.  Photodamage induced by Zinc(II)-phthalocyanine to microtubules, actin, alpha-actinin and keratin of HeLa cells.

Authors:  A Juarranz; J Espada; J C Stockert; A Villanueva; S Polo; V Domínguez; M Cañete
Journal:  Photochem Photobiol       Date:  2001-03       Impact factor: 3.421

6.  Sinoporphyrin sodium: a novel sensitizer in sonodynamic therapy.

Authors:  Jianmin Hu; Xiaobing Wang; Kun Zhang; Pan Wang; Xiaomin Su; Yixiang Li; Zuxian Huang; Quanhong Liu
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

7.  Multifunctional sonosensitizers in sonodynamic cancer therapy.

Authors:  Subin Son; Ji Hyeon Kim; Xianwen Wang; Chuangli Zhang; Shin A Yoon; Jinwoo Shin; Amit Sharma; Min Hee Lee; Liang Cheng; Jiasheng Wu; Jong Seung Kim
Journal:  Chem Soc Rev       Date:  2020-04-27       Impact factor: 54.564

8.  Hyperthermotherapy enhances antitumor effect of 5-aminolevulinic acid-mediated sonodynamic therapy with activation of caspase-dependent apoptotic pathway in human glioma.

Authors:  Donghui Ju; Fumio Yamaguchi; Guangzhi Zhan; Tadashi Higuchi; Takayuki Asakura; Akio Morita; Hideo Orimo; Shaoshan Hu
Journal:  Tumour Biol       Date:  2016-02-04

9.  Sinoporphyrin sodium based sonodynamic therapy induces anti-tumor effects in hepatocellular carcinoma and activates p53/caspase 3 axis.

Authors:  Enze Li; Yi Sun; Guixiang Lv; Yongning Li; Zhiguo Zhang; Zheng Hu; Wenwu Cao
Journal:  Int J Biochem Cell Biol       Date:  2019-01-17       Impact factor: 5.085

10.  Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice.

Authors:  Wenwen Yue; Liang Chen; Luodan Yu; Bangguo Zhou; Haohao Yin; Weiwei Ren; Chang Liu; Lehang Guo; Yifeng Zhang; Liping Sun; Kun Zhang; Huixiong Xu; Yu Chen
Journal:  Nat Commun       Date:  2019-05-02       Impact factor: 14.919

View more
  4 in total

Review 1.  Multifunctional Nanosystems Powered Photodynamic Immunotherapy.

Authors:  Yunong Ma; Fengfeng Xiao; Cuixia Lu; Liewei Wen
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

Review 2.  Application of nanosonosensitizer materials in cancer sono-dynamic therapy.

Authors:  Chaotao Hu; Biao Hou; Songlin Xie
Journal:  RSC Adv       Date:  2022-08-15       Impact factor: 4.036

Review 3.  Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges.

Authors:  Xiao Hu; Yu-Sen Zhang; Yi-Chao Liu; Na Wang; Xian-Tao Zeng; Ling-Ling Zhang
Journal:  J Nanobiotechnology       Date:  2022-10-04       Impact factor: 9.429

4.  TiSe2-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer.

Authors:  Libin Chen; Wang Xue; Jing Cao; Shengmin Zhang; Yiqing Zeng; Ling Ma; Xuechen Qian; Qing Wen; Yurong Hong; Zhan Shi; Youfeng Xu
Journal:  J Nanobiotechnology       Date:  2022-10-15       Impact factor: 9.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.